TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks

July 2000

Genentech is now introducing TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks.

TNKase is a modified version of Activase (alteplase, tPA). It's made by substituting 3 amino acids of the tPA enzyme.

TNKase and Activase have comparable efficacy for restoring blood flow and improving survival after a heart attack.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote